Descripción del proyecto
Revolución del proceso de producción de carnes alternativas
La creciente demanda de carne, en combinación con el intento de reducción de las emisiones totales de CO2 procedentes del ganado, ha generado la búsqueda de soluciones biotecnológicas para la producción de carne. Una de las principales prácticas introducidas para hacer frente a este reto es la producción de carne de cultivos celulares (CCM, por sus siglas en inglés), lograda mediante el crecimiento de células de carne a partir de una pequeña muestra de células madre recogidas del animal. El proyecto CCMeat, financiado con fondos europeos, introducirá un conjunto de factores de crecimiento innovadores, asequibles y sin endotoxinas diseñados específicamente para la industria de la CCM. CCMeat tiene como objetivo, mediante esta innovadora tecnología, ayudar a los productores de CCM a que comercialicen sus productos de carnes alternativas y contribuir a la reducción de las consecuencias negativas de la producción de carne convencional.
Objetivo
ORF Genetics is a female-lead plant biotechnology company biofarming protein in barley for use in medical research, stem cell technology and skincare. Since 2001, we have produced over 50 proteins, specializing in human growth factors (GFs) which regulate the growth and development of cells. Our main focus has been on GFs for skincare use and now with our team of over 80 qualified scientists, researchers, marketers and more, we are aiming at a larger market, the cell-cultured meat (CCM) industry. The CCMeat project removes the biggest hurdle CCM producers are facing to bring their alternative meat products to market. With innovations in our technology we will produce affordable, endotoxin-free growth factors designed specifically for CCM: the MESOkine™ line (patent to be filed in June 2020). This will be done by scaling cultivation from our 2000m2 state-of-the-art geothermally powered greenhouse in Iceland to in-field cultivation sites. We will also introduce a protein processing technology (patent to be filed in July 2020) that will substantially decrease production costs and lead to greater GF yields. By 2030, our MESOkine™ line will drop GF prices from 3000€/kg of cultured meat to approximately 0.7€/kg meat at scales necessary to produce over 7 million tonnes of meat. We are already providing samples to CCM customers and expect to reach a 40% market share within 5 years with our strong first mover advantage. MESOkine™ sales are expected to rise exponentially and reach profitability of €19 million by 2026. As the demand for meat continues to grow, this innovation will have a profound impact on our planet, enabling CCM to avert many of the negative consequences of conventional meat production. This includes reducing greenhouse gases by more than 250 million tonnes of CO2-eq emissions, deforestation by producing 7-52 times as much meat with one hectare of land, and antibiotic resistance by sparing over 1000 tonnes of livestock antibiotic use.
Ámbito científico
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- agricultural sciencesanimal and dairy sciencedomestic animalsanimal husbandry
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-EIC-SMEInst-2018-2020-4
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
IS-203 KOPAVOGUR
Islandia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.